April 12, 2022 — The American College of Cardiology has issued an expert consensus decision pathway for the evaluation and management of adults with key cardiovascular consequences of COVID-19. The document discusses myocarditis and other types of myocardial involvement, patient-centered approaches for long COVID and guidance on resumption of exercise following COVID-19. The clinical guidance was published in the Journal of the American College of Cardiology.
“The best means to diagnose and treat myocarditis and long COVID following SARS-CoV-2 infection continues to evolve,” said Ty Gluckman, MD, MHA, co-chair of the expert consensus decision pathway. “This document attempts to provide key recommendations for how to evaluate and manage adults with these conditions, including guidance for safe return to play for both competitive and non-competitive athletes.”
Myocarditis, or inflammation of the heart, is a condition defined by the presence of cardiac symptoms (chest pain, shortness of breath, palpitations), an elevated cardiac troponin (biomarker of cardiac injury), and abnormal electrocardiographic (ECG), cardiac imaging (echocardiogram, cardiac magnetic resonance imaging) and/or cardiac biopsy findings.
Although rare, myocarditis with COVID-19 is more commonly seen in men. Because myocarditis is associated with a higher risk of cardiac complications, a proactive management plan should be in place to care for these individuals. For patients with mild or moderate forms of myocarditis, hospitalization is recommended to closely monitor for worsening symptoms, while undergoing follow-up testing and treatment. Patients with severe myocarditis should ideally be hospitalized at centers with expertise in advanced heart failure, mechanical circulatory support and other advanced therapies.
Myocarditis following COVID-19 mRNA vaccination is also rare. As of May 22, 2021, the U.S. Vaccine Adverse Event Reporting System noted rates of 40.6 cases per million after the second vaccine dose among male individuals aged 12-29 years and 2.4 cases per million among male individuals aged >30 years. Corresponding rates in female individuals were 4.2 and 1 cases per million, respectively. Although most cases of myocarditis following COVID-19 mRNA vaccination are mild, it should be diagnosed and treated similarly to myocarditis following COVID-19 infection. Currently approved COVID-19 mRNA vaccines are highly effective, and the benefit-to-risk ratio is very favorable across all demographic groups evaluated thus far.
Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly referred to as long COVID, is a condition reported by up to 10-30% of infected individuals. It is defined by a constellation of new, returning or persistent health problems experienced by individuals four or more weeks after COVID-19 infection. While individuals with this condition may experience wide-ranging symptoms, tachycardia, exercise intolerance, chest pain and shortness of breath represent some of the symptoms that draw increased attention to the cardiovascular system.
The writing committee has proposed two terms to better understand potential etiologies for those with cardiovascular symptoms:
- PASC-CVD, or PASC-Cardiovascular Disease, refers to a broad group of cardiovascular conditions (including myocarditis) that manifest at least four weeks after COVID-19 infection.
- PASC-CVS, or PASC-Cardiovascular Syndrome, includes a wide range of cardiovascular symptoms without objective evidence of cardiovascular disease following standard diagnostic testing.
In general, patients with long COVID and cardiovascular symptoms should undergo evaluation with laboratory tests, ECG, echocardiogram, ambulatory rhythm monitor and/or additional pulmonary testing based on the clinical presentation. Cardiology consultation is recommended for abnormal test results, with additional evaluation based on the suspected clinical condition (e.g., myocarditis).
Because multiple factors likely underlie PASC-CVS, evaluation and management may be best driven by the predominant cardiovascular symptom(s). For those with tachycardia and exercise intolerance, increased bedrest and/or a decline in physical activity may trigger cardiovascular deconditioning with progressive worsening of symptoms.
“There appears to be a ‘downward spiral’ for long COVID patients. Fatigue and decreased exercise capacity lead to diminished activity and bedrest, in turn leading to worsening symptoms and decreased quality of life,” said Nicole Bhave, MD, co-chair of the expert consensus decision pathway. “The writing committee recommends a basic cardiopulmonary evaluation performed upfront to determine if further specialty care and formalized medical therapy is needed for these patients.”
For PASC-CVS patients with tachycardia and exercise intolerance, upright exercise (walking or jogging) should be replaced with recumbent or semi-recumbent exercise (rowing, swimming or cycling) to avoid worsening fatigue. Exercise intensity and duration should be low initially, with gradual increases in exercise duration over time. Transition back to upright exercise can be done as one’s symptoms improve. Additional interventions (increased salt and fluid intake, elevation of the head during sleep, support stockings) and pharmacological treatments (beta-blockers) should be considered on a case-by-case basis.
Return to Play
Observation of cardiac injury among some patients hospitalized with COVID-19, coupled with uncertainty around cardiovascular sequelae after mild illness, fueled early apprehension regarding the safety of competitive sports for athletes recovering from COVID-19 infection. Subsequent data from large registries have demonstrated an overall low prevalence of clinical myocarditis, without a rise in the rate of adverse cardiac events. Based on this, updated guidance is provided with a practical, evidence-based framework to guide resumption of athletics and intense exercise training.
For athletes recovering from COVID-19 with ongoing cardiopulmonary symptoms (chest pain, shortness of breath, palpitations, lightheadedness) or those requiring hospitalization with increased suspicion for cardiac involvement, further evaluation with triad testing—an ECG, measurement of cardiac troponin and an echocardiogram—should be performed. For those with abnormal test results, further evaluation with cardiac magnetic resonance imaging (cardiac MRI) should be considered. Individuals diagnosed with clinical myocarditis should abstain from exercise for three to six months.
Cardiac testing is not recommended for asymptomatic individuals following COVID-19 infection. Individuals should abstain from training for three days to ensure that symptoms do not develop. For those with mild or moderate non-cardiopulmonary symptoms (fever, lethargy, muscle aches), training may resume after symptom resolution. For those with remote infection (≥ three months) without ongoing cardiopulmonary symptoms, a gradual increase in exercise is recommended without the need for cardiac testing.
Based on the low prevalence of myocarditis observed in competitive athletes with COVID-19, the authors note that these recommendations can be reasonably applied to high-school athletes (aged ≥14 years) along with adult recreational exercise enthusiasts. Future study is needed, however, to better understand how long cardiac abnormalities persist following COVID-19 infection and the role of exercise training in long COVID.
For more information: www.acc.org
Related Long-COVID Content:
MRI Sheds Light on COVID Vaccine-Associated Heart Muscle Injury
What We Know About Cardiac Long-COVID Two Years Into the Pandemic
VIDEO: Long-term Cardiac Impacts of COVID-19 Two Years Into The Pandemic — Interview with Aaron Baggish, M.D.
VIDEO: Long-COVID Presentations in Cardiology at Beaumont Hospital — Interview with Justin Trivax, M.D.
VIDEO: Cardiac Presentations in COVID Long-haulers at Cedars-Sinai Hospital — Interview with Siddharth Singh, M.D.
Find more COVID news and videos
Related COVID Content:
COVID-19 Fallout May Lead to More Cancer Deaths
Kawasaki-like Inflammatory Disease Affects Children With COVID-19
FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets
CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4
Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents
Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination
Overview of Myocarditis Cases Caused by the COVID-19 Vaccine
Case Study Describes One of the First U.S. Cases of MIS-C
NIH-funded Project Wants to Identify Children at Risk for MIS-C From COVID-19
For more information: www.acc.org